The overall goals of the Cancer Regulatory Networks (CRN) Program are to study regulatory networks within the cancer cell and between cancer cells and the tumor environment. The Program has three scientific themes: 1) Oncogenic and Tumor Suppressor Signaling: the analysis of signal transduction pathways that orchestrate the oncogenic phenotype;2) Tumor Microenvironment: the study of host cells that interact with tumor cells to influence growth, the inflammatory response, and metastasis;and 3) Cancer Systems Biology: the use of model-based approaches to generate testable hypotheses about genetic drivers of cancer, to dissect and interrogate gene regulatory networks, and to identify Master Regulator genes. The latter theme was recently formulated to reflect a major HICCC strength in cancer systems biology (which is also embodied in the new Department of Systems Biology established by Columbia University in 2013). The CRN Program promotes collaboration among its members (intra-programmatic interactions) and with other HICCC members in the basic science, disease-specific and population sciences programs (inter- programmatic interactions), as well as with cancer scientists at other NCI-supported Cancer Centers nationwide. The Program provides a forum in which CRN investigators share their latest discoveries and seek translational applications of their work. The Program also stimulates research by providing investigator feedback to the HICCC Senior Leadership Team (SLT) and the HICCC Shared Resources (SRs). The Program actively seeks opportunities for clinical translation of CRN basic science discoveries, as evidenced by recent awards supporting several NCI centers of excellence to study druggable targets and drug mechanisms;including Cancer Target Discovery and Development (CTD2), Integrative Cancer Biology Programs for Cancer Systems Biology, and centers in the Library of Integrated, Network Based Cellular Signatures. The development, assembly, and interrogation of tumor regulatory models for virtually all tumor types represented in TCGA, TARGET, and COSMIC, has led to an N of 1 initiative at Columbia to study oncogene-induced dependencies that can be targeted pharmacologically on an individual patient basis. The CRN Program consists of 40 members (38 full, 2 clinical scientists) associated with nine basic science and nine clinical departments at Columbia University. The total number of cancer-related publications by the current Program members since the previous site visit is 539, with 2 1% inter-programmatic and 5% intra-programmatic publications. Of these, 37% appeared in high impact journals with impact factor >10 and 12% with an impact factor >20. During the most recent funding period, the CRN Program received funding of $17.8M (direct costs) in cancer-relevant grant support, including $7.0M (direct costs) in NCI funding.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013696-40
Application #
8753109
Study Section
Subcommittee G - Education (NCI)
Project Start
1997-07-04
Project End
2019-06-30
Budget Start
2014-07-17
Budget End
2015-06-30
Support Year
40
Fiscal Year
2014
Total Cost
$66,637
Indirect Cost
$24,989
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Bassuk, Alexander G; Sujirakul, Tharikarn; Tsang, Stephen H et al. (2014) A novel RPGR mutation masquerading as Stargardt disease. Br J Ophthalmol 98:709-11
Li, Yao; Wu, Wen-Hsuan; Hsu, Chun-Wei et al. (2014) Gene therapy in patient-specific stem cell lines and a preclinical model of retinitis pigmentosa with membrane frizzled-related protein defects. Mol Ther 22:1688-97
Wert, Katherine J; Sancho-Pelluz, Javier; Tsang, Stephen H (2014) Mid-stage intervention achieves similar efficacy as conventional early-stage treatment using gene therapy in a pre-clinical model of retinitis pigmentosa. Hum Mol Genet 23:514-23
Shen, Sherry; Sujirakul, Tharikarn; Tsang, Stephen H (2014) Next-generation sequencing revealed a novel mutation in the gene encoding the beta subunit of rod phosphodiesterase. Ophthalmic Genet 35:142-50
Palomero, Teresa; Couronné, Lucile; Khiabanian, Hossein et al. (2014) Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas. Nat Genet 46:166-70
Higuchi-Sanabria, Ryo; Pernice, Wolfgang M A; Vevea, Jason D et al. (2014) Role of asymmetric cell division in lifespan control in Saccharomyces cerevisiae. FEMS Yeast Res 14:1133-46
Lam, A T; Curschellas, C; Krovvidi, D et al. (2014) Controlling self-assembly of microtubule spools via kinesin motor density. Soft Matter 10:8731-6
Olszak, Torsten; Neves, Joana F; Dowds, C Marie et al. (2014) Protective mucosal immunity mediated by epithelial CD1d and IL-10. Nature 509:497-502
Murtomaki, Aino; Uh, Minji K; Kitajewski, Chris et al. (2014) Notch signaling functions in lymphatic valve formation. Development 141:2446-51
Nong, Eva; Lee, Winston; Merriam, Joanna E et al. (2014) Disease progression in autosomal dominant cone-rod dystrophy caused by a novel mutation (D100G) in the GUCA1A gene. Doc Ophthalmol 128:59-67

Showing the most recent 10 out of 142 publications